NextWave Pharmaceuticals Inc.'s investors are in line for at least a 2.5X return on the $105 million they have put into the CNS company after Pfizer Inc. (NYSE:PFE) exercised an option to acquire it last week. The news follows last month's FDA approval of the biotech's ADHD drug Quillivant XR.

The pharma paid $20 million for the option in 2012. In exercising